Within the Types dimension, the market is stratified into four principal assay families: Molecular (PCR and NGS‑based), Immunoassay (ELISA and lateral‑flow), Culture‑based (traditional agar and automated broth systems), and Serology (antibody detection). Molecular tests, comprising about 40 % of sales, command premium pricing due to their high sensitivity, species‑level identification, and ability to detect resistance markers, thereby expanding market value despite higher capital costs. Immunoassays hold roughly 30 % share, offering a balance of speed and moderate cost, and are widely adopted in both hospital labs and point‑of‑care environments. Culture‑based methods, while older, retain a 20 % slice of the market because of their role in antifungal susceptibility testing and regulatory acceptance. Serology, the smallest at 10 %, serves niche applications such as monitoring chronic colonization or research settings. The relative contributions of these test types collectively define the market taxonomy and influence strategic investment across the Candida Infection Testing sector.